Hancock Jaffe Laboratories Inc EPS
What is the EPS of Hancock Jaffe Laboratories Inc?
The EPS of Hancock Jaffe Laboratories Inc is N/A
What is the definition of EPS?
Earnings per share (EPS) is the portion of a company’s profit allocated to each outstanding share of common stock. It is adjusted for dilution and calculated over trailing twelve months.
ttm (trailing twelve months)
Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. Preferred stock rights have precedence over common stock. Therefore, dividends on preferred shares are subtracted before calculating the EPS. When preferred shares are cumulative, annual dividends are deducted whether or not they have been declared. Dividends in arrears are not relevant when calculating EPS. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.
What does Hancock Jaffe Laboratories Inc do?
Hancock Jaffe Laboratories specializes in developing and manufacturing bioprosthetic (tissue-based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has two lead product candidates: the VenoValveÒ, a porcine-based valve which is intended to be surgically implanted in the deep venous system of the leg to treat reflux associated with Chronic Venous Insufficiency, and the CoreoGraftÒ, a bovine tissue-based off-the-shelf conduit intended to be used for coronary artery bypass surgery.